Release Date: 30-Aug-2023
For several years in a row, the bispecific antibody Hemlibra has been one of Roche's best-selling medicines, and this trend was maintained in 2022 and the first half of 2023. Roche reported Hemlibra sales of CHF 2087 million (US$ 2379.18 million) through June 2023, a 20% increase over the same period in 2022. The increase in sales value has been attributed to increased drug adoption and higher selling price. For the full year 2022, Hemlibra’s global sales were reported to be CHF 3823 Million (US$ 4,358.22 Million). Hemlibra has emerged as one of the finest therapies for Hemophilia A, which has helped it dominate the global market for bispecific antibodies.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028
https://www.kuickresearch.com/report-us-bispecific-antibodies-market